FDA Confirms Prasugrel Advisory Committee Review; What Will Panel Membership Entail?
This article was originally published in The Pink Sheet Daily
Executive Summary
Lilly/Daiichi’s platelet inhibitor prasugrel will be subject of Feb. 3 advisory committee; outcome could hinge on makeup of expert panel.
You may also be interested in...
Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
Firm reports ’08 net loss from ImClone deal and Zyprexa settlement
Lilly’s 2009 Growth Rides On Prasugrel; Advisory Committee’s Review Is Feb. 3
Firm reports ’08 net loss from ImClone deal and Zyprexa settlement
FDA’s Rollover Reviews: Missed Deadlines Could Inflate 2009 Approval Tally
FDA is heading into 2009 with at least a dozen missed review deadlines held over from 2008 - potentially setting up the agency and industry for what could be an unusually higher number of drug and biologic approvals this year